Sees FY24 revenue $620M-$650M, consensus $660.71M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
- Regeneron, Sanofi announce MHLW in Japan approves Dupixent
- Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
- Regeneron price target raised to $1,060 from $920 at Argus
- Regeneron exec LaRosa sells 1,000 common shares